However, in our study, HER2 status was not an independent factor affecting the prognosis of patients with progressive gastric cancer receiving immunotherapy, which may be related to the fact that immunotherapy significantly improved the prognosis of patients with HER2-negative gastric cancer, compensating for the pre-existing survival differences across HER2 status. Here, ERBB2 is linked to gastric cancer.